Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?
Keywords:
monoclonal antibody, SarcoidosisAbstract
Sarcoidosis is a multi-system disorder characterized by the formation of non-caseating granulomas. It is a disorder of unknown etiology. Interferon-induced sarcoidosis is a well-known phenomenon. However, in the past few years, few cases have come forward in which after treatment with a monoclonal antibody, Alemtuzumab, patients developed sarcoidosis. This antibody targets the pan-lymphocyte CD52 antigen found on both human lymphoid and myeloid cells and is used in the treatment of Relapsing Remitting Multiple Sclerosis, leukemia, etc. Patients, in these cases, after a few years of treatment developed sarcoidosis but fortunately responded well to the treatment, if needed.
References
Doyle MK, Berggren R, Magnus JH. Interferon-induced Sarcoidosis. J Clin Rheumatol. 2006 Oct;12(5):241-8. doi: 10.1097/01.rhu.0000240035.67652.9d.
Graf J, Ringelstein M, Lepka K, et al. Acute Sarcoidosis in a multiple sclerosis patient after Alemtuzumab treatment. Mult Scler. 2018 Nov;24(13):1776-1778. doi: 10.1177/1352458518771276. Epub 2018 Oct 11.
Willis MD, Hope-Gill B, Flood-Page P, et al. Sarcoidosis following Alemtuzumab treatment for multiple sclerosis. Mult Scler. 2018 Nov;24(13):1779-1782. doi: 10.1177/1352458518790391. Epub 2018 Oct 11.
Erlich-Malona N, Cahill J, Chaudhry S, Martin J, Rizvi S. Cardiac Sarcoidosis requiring ICD placement and immune thrombocytopenia following Alemtuzumab treatment for multiple sclerosis. Mult Scler Relat Disord. 2021 Jan;47:102599. doi: 10.1016/j.msard.2020.102599. Epub 2020 Oct 28.
Thachil J, Jadhav V, Gautam M, et al. The development of Sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution. Br J Haematol. 2007 Aug;138(4):559-60. doi: 10.1111/j.1365-2141.2007.06687.x. Epub 2007 Jun 22.
Rezvany MR, Tehrani MJ, Karlsson C, et al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol. 2006 Nov;135(4):475-85. doi: 10.1111/j.1365-2141.2006.06324.x. Epub 2006 Sep 22. PMID: 16995884.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Misbah Nizamani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
